Edward McMillan, MD
Cardiovascular Disease · Charlotte, NCNPI 1831199876
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Novartis at 55.1% of the total. Reporting peaked in 2019 at $5,830 and has fallen 87.3% since, to $743 in 2025.
Across 197 payments — averaging $50.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Abbott$2K
- Kestra Medical Technology Services, Inc.$493
- Boston Scientific$482
- Johnson & Johnson$260
- Amgen$241
- plus $1K from 19 others
Across 140 payments — averaging $1152.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$81K
- Boehringer Ingelheim International GmbH$50K
- Boehringer Ingelheim Pharma GmbH & Co.kg$27K
- Abbott$4K
What the payments were for
- Speaking & faculty fees$4,48045%
- Travel & lodging$1,00710%
- Food & beverage$4,46645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 42 | $5,486 |
| Abbott | 22 | $1,566 |
| Kestra Medical Technology Services, Inc. | 37 | $493 |
| Boston Scientific | 20 | $482 |
| Johnson & Johnson | 17 | $260 |
| Amgen | 12 | $241 |
| E.r. Squibb & Sons, L.L.C. | 8 | $230 |
| AstraZeneca | 7 | $204 |
| Edwards Lifesciences | 1 | $143 |
| Esperion Therapeutics, Inc. | 1 | $103 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $103 |
| Akcea Therapeutics, Inc. | 1 | $91 |
| Boehringer Ingelheim | 3 | $82 |
| Scpharmaceuticals Inc. | 3 | $80 |
| Bayer | 4 | $79 |
| Medtronic(2 entities) | 2 | $67 |
| Stryker | 1 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Abiomed | 1 | $26 |
| Merck | 1 | $25 |
| Cvrx, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$4,685
- Mitra Clip system$952
- MitraClip$157
- Edwards SAPIEN 3 Transcatheter Heart Valve$143
- CAMZYOS$125
- WAINUA$113
- NEXLIZET$103
- NEXLETOL$103
How this compares
$9,953 in reported general payments places this provider in the 80th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 530 | $528,511 |
| VyndamaxTafamidis | 24 | $524,970 |
| EntrestoSacubitril/Valsartan | 251 | $272,752 |
| VyndaqelTafamidis Meglumine | 11 | $230,916 |
| Repatha SureclickEvolocumab | 130 | $93,992 |
| XareltoRivaroxaban | 96 | $92,671 |
| JardianceEmpagliflozin | 59 | $49,976 |
| Praluent PenAlirocumab | 46 | $31,387 |
| FarxigaDapagliflozin Propanediol | 36 | $26,696 |
| Repatha SyringeEvolocumab | 19 | $15,564 |
| Ezetimibe | 301 | $5,636 |
| Atorvastatin Calcium | 451 | $5,093 |
| Rosuvastatin Calcium | 488 | $4,706 |
| Metoprolol Succinate | 331 | $3,896 |
| Clonidine | 14 | $2,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $5,486 | $272,752251 claims |
| Johnson & JohnsonXarelto | $260 | $92,67196 claims |
| Boehringer IngelheimJardiance | $82 | $49,97659 claims |
| AstraZenecaFarxiga | $204 | $26,69636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Charlotte
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
- Rohit MehtaCharlotte$189K
- Brian PowellCharlotte$160K
- Nicole Cyrille-SupervilleCharlotte$115K
- Noreen KellyCharlotte$84K
- Dermot PhelanCharlotte$76K
- Charles SimontonCharlotte$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.